The Fly | BIVI

Novel Mechanism of Action: NE3107's unique dual inhibition of ERK and TNF-α pathways offers a differentiated approach to neuroinflammation and insulin resistance, core drivers of neurodegeneration.

Targeting Core Disease Pathologies: The focus on neuroinflammation and insulin resistance addresses fundamental mechanisms underlying Alzheimer's and Parkinson's, potentially offering more disease-modifying effects than symptomatic treatments.

Positive Clinical Validation: Encouraging Phase 2 clinical trial data in both Alzheimer's and Parkinson's diseases, showing improvements in cognitive function, motor symptoms, and biomarker reduction.

Clinical Trial Failure Risk: Lead product candidates may not achieve primary endpoints in ongoing or future clinical trials, leading to significant delays, increased costs, or complete discontinuation of development.

Regulatory Approval Uncertainty: Even with successful clinical trial results, securing necessary regulatory approvals from agencies like the FDA is not guaranteed and can be a lengthy, unpredictable, and expensive process.

Capital Needs & Dilution: Biovie operates at a net loss and will require substantial additional financing to fund its operations and clinical trials, which may lead to significant future shareholder dilution or an inability to continue operations.

Charts

Novel Mechanism of Action: NE3107's unique dual inhibition of ERK and TNF-α pathways offers a differentiated approach to neuroinflammation and insulin resistance, core drivers of neurodegeneration.